Purple Biotech (PPBT)

• Market cap: $5.21M
• 1 day: -0.98%
• 5 days: -6.43%
• 1 month: -0.41%
• 3 months: -79.01%
• 6 months: -78.38%
• Year to date: -87.42%
• 1 year: -87.97%
• 5 years: -99.39%
• 10 years: -99.91%
• Sector: Healthcare
• Industry: Biotechnology

About: Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Employees: 7